**Table S2- The characteristics of included studies.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| No． | Study | Country | Number of eyes, IVC/ IVR | Follow-up (months) | Treatment regimen | Outcomes |
| 1 | Liu et al. 2015 [13] | China | 30/30 | 3 | 1.5mgIVC/0.5mgIVRMonthly for 3 months | VA, CMT, IOP, CNV leakage, VEGF, CRP |
| 2 | Lv et al. 2016 [14] | China | 42/42 | 3 | 0.5mgIVC/0.5mgIVRMonthly for 3 months then as-needed | VA, CMT, OAEs |
| 3 | Zhang et al. 2017 [15] | China | 20/20 | 3 | 0.5mgIVC/0.5mgIVRMonthly for 3 months | BCVA, CMT, CNV leakage, OAEs |
| 4 | Shen et al. 2017 [18] | China | 52/51 | 12 | 0.5mgIVC/0.5mgIVRMonthly for 3 months then as-needed | VA, CMT, CNV leakage |
| 5 | Zheng et al. 2017 [16] | China | 42/43 | 3  | 0.5mgIVC/0.5mgIVRMonthly for 3 months then as- needed | VA, CMT |
| 6 | Wang et al. 2017 [17] | China | 38/38 | 3 | 0.05mLIVR/0.05mLIVCNA | VA, CMT |
| 7 | Lei et al. 2018 [21] | China | 30/30 | 3, 6 | 0.5mgIVC/0.5mgIVRMonthly for 3 months | VA, CMT |
| 8 | Liu et al. 2018 [19] | China | 35/34 | 3 | 0.5mgIVC/0.5mgIVRMonthly for 3 months then as-needed | VA, CMT |
| 9 | Shu et al. 2018 [20] | China | 40/40 | 3  | 1.0mgIVC/1.0mgIVRMonthly for 3 months | VA, CMT, CNV leakage, OAEs |
| 10 | Zhang et al. 2018 [23]  | China | 34/34 | 3, 6 | 0.5mgIVC/0.5mgIVRMonthly for 3 months | VA, CMT, OAEs |
| 11 | Wei et al. 2018 [22] | China | 35/35 | 3 | 1.5mgIVC/0.5mgIVRMonthly for 3 months | VA, IOP, VEGF, CRP, OAEs |

**Table S2- The characteristics of included studies (continued).**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| No． | Study | Country | Number of eyes, IVC/ IVR | Follow-up (months) | Treatment regimen | Outcomes |
| 12 | Tong et al. 2019 [26] | China | 50/50 | 12  | 0.5mgIVC/0.5mgIVRMonthly for 3 months | VA, CMT, CNV leakage |
| 13 | Liang et al. 2019 [25] | China | 30/30 | 3  | 0.5mgIVC/0.5mgIVRMonthly for 3 months | VA, CMT, IOP, VEGF, CRP, OAEs |
| 14 | Xu et al. 2019 [27] | China | 30/30 | 3 | 0.5mgIVC/0.5mgIVRMonthly for 3 months | VA, CMT, CNV leakage |
| 15 | Xue et al. 2019 [24] | China | 51/51 | 6 | NA | VA, CMT, OAEs |
| 16 | Bai et al. 2019 [28] | China | 55/55 | 3 | 0.5mgIVC/0.5mgIVRNA | VA, CNV leakage, CMT |

Abbreviations: IVC: Intravitreal injection of conbercept; IVR: Intravitreal injection of ranibizumab; VA: visual acuity; CMT: central macular thickness; CNV: choroidal neovascularization; IOP: intraocular pressure; VEGF: vascular endothelial growth factor; CRP: C- reactive protein; OAEs: ocular adverse events.